Top Gene Therapy Companies

The global gene therapy market is expected to be driven by rapidly increasing investments in gene technology R&D, coupled with the subsequent rise in the prevalence of genetic disorders. Rising use of gene therapies for the treatment of diseases such as hemophilia, cystic fibrosis, and specific cancers is also slated to create new opportunities for market players. Improved efficacy and safety of gene editing technologies such as CRISPR-Cas9 is also anticipated to generate new business scope in the long run. Developed countries with high public and private spending on genetic technology R&D are slated to spearhead the business scope of gene therapy companies in the long run.

Industry Overview

According to SkyQuest Technology “Gene Therapy Market By Gene Type (Antigen, Cytokine), By Therapy type (Gene silencing therapy, Cell replacement therapy), By Vector type, By Delivery Method, By Route Of Administration, By Application, By Region - Industry Forecast 2025-2032,” Global gene therapy market is projected to grow at a CAGR of over 19.1% by 2032, as investments in gene editing technologies increase substantially. Increase in incidence of cancer and willingness of people to use gene therapy for the treatment of the same is also slated to benefit gene therapy companies in the long run. Adoption of precision medicine practices and development of favourable regulatory frameworks are also predicted to create long term growth for market players involved.

Top 10 Global Gene Therapy Companies

1. Krystal Biotech

Krystal Biotech is a commercial-stage genetic medicines company focused on dermatologic and other rare diseases using AAV and related delivery technologies. Founded in 2015 and with United States operations based in Pittsburgh, Krystal won FDA approval for Vyjuvek® (a topical genetic therapy) and has expanded into manufacturing and commercial supply to support product launches and pipeline programs. Recent quarterly and annual reports show rapid revenue growth following commercialization activity.

2. CRISPR Therapeutics

CRISPR Therapeutics, established in 2013 and headquartered in Zug, Switzerland (with major United States presence), is one of the founding companies translating CRISPR-Cas9 editing into human therapeutics. Its pipeline spans ex-vivo programs (e.g., edited cell therapies for hemoglobinopathies and oncology) and in-vivo programs developed with partners. Financials show modest product/partner revenue to date while R&D and collaboration income are material to its results.

3. Beam Therapeutics

Beam Therapeutics (founded 2017) is a leader in precision base editing and developing prime-editing approaches intended to precisely rewrite single DNA bases without double-strand breaks. Headquartered in Cambridge, MA, Beam pursues both in-vivo and ex-vivo programs across genetic diseases and oncology. The company is clinical-stage and reports revenue primarily from collaborations and milestone-related items; 2024 revenues and TTM figures are in the tens of millions.

4. Intellia Therapeutics

Intellia Therapeutics, founded in 2014 and based in Cambridge, MA, develops CRISPR-based in-vivo gene editing (notably liver-directed programs) and ex-vivo cell engineering. Intellia’s strategic focus includes optimized delivery (LNPs) for systemic editing and early clinical readouts in hereditary and metabolic diseases. The company’s reported revenues to date are driven by partnerships and early program milestones, while R&D remains the dominant activity.

5. Korro Bio

Korro Bio (est. 2018) is an RNA-editing company developing a platform called Oligonucleotide Promoted Editing of RNA (OPERA) to create reversible, programmable edits at the RNA level. Headquartered in Cambridge, MA, Korro is an early-stage biotech focused on neurology and metabolic indications, positioning RNA editing as a potentially safer, tunable approach versus permanent DNA edits. Public filings and profile databases classify Korro as small / clinical discovery stage with limited commercial revenue so far.

6. Neurogene

Neurogene, founded in 2018 and headquartered in New York, is dedicated to AAV-based gene therapies for rare and severe neurological disorders. Focused on CNS delivery and durable expression in the brain, Neurogene combines proprietary capsids and clinical programs targeting ultra-rare paediatric diseases. The company is clinical-stage; its investor and corporate filings describe active clinical development and scale-up activities rather than significant commercial product revenue to date.

7. Sangamo Therapeutics

Sangamo (founded 1995, based in Brisbane, CA) is a long-standing genome-engineering company that developed zinc-finger nuclease (ZFN) technologies and expanded into gene regulation, gene insertion, and in-vivo editing programs. Sangamo’s pipeline includes candidates for genetic and rare diseases, and it reports revenue from partnerships, collaborations, and milestone events. The company has experienced program-level volatility (partner changes and program reprioritizations) but remains a major platform player in gene therapy and genome engineering.

8. MeiraGTx

MeiraGTx (formed as a public company in 2018) is a vertically integrated genetic medicines company focused on ophthalmology and neurology, with built-in vector manufacturing and clinical capabilities. Headquartered in New York (with international operations), MeiraGTx advances AAV-based ocular and CNS programs and offers CMC and manufacturing services that support both internal programs and external collaborations. Reported revenue in recent filings is in the low tens of millions driven by service and collaboration income while clinical R&D continues to expand.

9. Verve Therapeutics

Verve Therapeutics (founded 2018, Boston) specifically targets cardiovascular disease using in-vivo gene editing (CRISPR) aimed at permanently lowering lifelong risk by inactivating liver genes such as PCSK9 and ANGPTL3. Verve progressed rapidly from preclinical to early clinical studies and has drawn major strategic interest—most recently being the subject of acquisition reports and partnership activity—underscoring the commercial and scientific promise of single-course cardiovascular gene therapies. Public filings and market reports show early revenue activity consistent with a clinical-stage biotech.

10. Prime Medicine

Prime Medicine, founded by leaders in prime-editing science, is building a platform (PRISM / prime editing) to make precise, one-time corrective DNA edits for monogenic diseases. Based in Cambridge, MA, Prime is clinical-stage/late-preclinical for several programs and focuses on platform expansion, partnership deals, and advancing IND-enabling studies. Revenue is currently limited to collaborations and grants while R&D and platform build-out are the main activities.

Other Leading Global Gene Therapy Companies

• Taysha Gene Therapies (United States)
• enGene (Canada)
• Voyager Therapeutics (United States)
• Poseida Therapeutics (United States)
• uniQure (Netherlands)
• Editas Medicine (United States)
• Benitec Biopharma (United States)
• Cellectis S.A. (France)
• Adverum Biotechnologies (United States)
• Generation Bio (United States)

Conclusion

The global gene therapy market is anticipated to expand at a rapid pace, but the adoption is expected to hamper by limited reimbursement for novel therapies. Ethical and safety concerns associated with gene therapies are also estimated to have a negative impact on gene therapy adoption across the world. Use of advanced technologies and emphasis on spreading more awareness regarding the benefits of gene therapy remains the prime focus of almost all companies. Collaborations are expected to be highly important for fast paced R&D and commercialization. Supportive government initiatives to boost gene technology development and expansion of the biotechnology sector are also slated to ensure sustained growth for gene therapy providers through 2032 and beyond.